Podcasts

Recent Episodes

August 7, 2026

Greater Flexibility and Improved QOL Represent Key Potential Benefits With Liquid TKI Formulations: With Jonathan Trent, MD, PhD

August 4, 2026

An Ophthalmologist Guides Oncologists and Patients Through ADC-Related Eye Toxicities: With Sara Nunnery, MD, MSCI; and Sarah Sunshine, MD

August 3, 2026

From Trials to the Clinic: Incorporating New Advances in Metastatic TNBC

Douglas W. Sborov, MD, MS, discussed the FDA approval of isatuximab for subcutaneous injection in multiple myeloma indications.

July 31, 2026

FDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS

Solange Peters, MD, PhD, University Hospital of Lausanne

July 31, 2026

Positioning PD-L1/VEGF Bispecifics in First-Line Non–Small Cell Lung Cancer: With Solange Peters, MD, PhD

July 31, 2026

Precision Oncology, Bispecific Antibodies, and Next-Generation Targeted Therapies Are Reshaping NSCLC Care: With Chandler Park, MD; Stephen V. Liu, MD

July 30, 2026

Biomarker-Driven Shifts Signal the Next Generation of mCRC Therapies: With Tanios S. Bekaii-Saab, MD

July 30, 2026

Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD

Marlana M. Orloff, MD, the Alexander & Johnston Family Endowed Clinical Director in Uveal Melanoma, and associate professor at Thomas Jefferson University Hospital

July 29, 2026

Sequencing Systemic and Liver-Directed Therapy in HLA-A*02:01–Negative Metastatic Uveal Melanoma: With Marlana M. Orloff, MD

July 28, 2026

Experts Bridge Oncology and Neurology to Catch LEMS Earlier in SCLC: With Misty D. Shields, MD, PhD; Triparna Sen, MD, PhD, MS; and Ditte Primdahl, MD

All series

All Podcasts

Greater Flexibility and Improved QOL Represent Key Potential Benefits With Liquid TKI Formulations: With Jonathan Trent, MD, PhD

ByJonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center

August 7th 2026

Jonathan Trent, MD, PhD, discusses the clinically available TKIs for GIST and the potential benefits of liquid TKI formulations for this disease.

An Ophthalmologist Guides Oncologists and Patients Through ADC-Related Eye Toxicities: With Sara Nunnery, MD, MSCI; and Sarah Sunshine, MD

BySara Nunnery, MD, MSCI,Sarah Sunshine, MD

August 4th 2026

Drs Nunnery and Sunshine discuss how breast cancer therapies affect the eye, beginning with a primer on ocular anatomy.

From Trials to the Clinic: Incorporating New Advances in Metastatic TNBC

August 3rd 2026

OncLive On Air®

FDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS

ByDouglas W. Sborov, MD, MS

July 31st 2026

Douglas W. Sborov, MD, MS, discussed the FDA approval of isatuximab for subcutaneous injection in multiple myeloma indications.

Positioning PD-L1/VEGF Bispecifics in First-Line Non–Small Cell Lung Cancer: With Solange Peters, MD, PhD

BySolange Peters, MD, PhD

July 31st 2026

Dr Peters discussed the rationale for pairing antiangiogenic activity with checkpoint inhibition upfront in NSCLC, rather than sequencing them.

Precision Oncology, Bispecific Antibodies, and Next-Generation Targeted Therapies Are Reshaping NSCLC Care: With Chandler Park, MD; Stephen V. Liu, MD

ByChandler Park, MD, MSc, FACP,Stephen Liu, MD

July 31st 2026

Drs Park and Liu discuss precision oncology, bispecific antibodies, and next-generation targeted therapies in NSCLC.

Biomarker-Driven Shifts Signal the Next Generation of mCRC Therapies: With Tanios S. Bekaii-Saab, MD

ByTanios Bekaii-Saab, MD, FACP

July 30th 2026

Dr Bekaii-Saab discusses the current state of the metastatic colorectal cancer treatment landscape and potential future research directions.

Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD

ByJohn N. Allan, MD

July 30th 2026

John N. Allan, MD, discusses all things regarding fixed-duration regimens in CLL from a review of the most pivotal data for the topic.

Sequencing Systemic and Liver-Directed Therapy in HLA-A*02:01–Negative Metastatic Uveal Melanoma: With Marlana M. Orloff, MD

ByMarlana M. Orloff, MD

July 29th 2026

Dr Orloff discusses the distinct biology of uveal melanoma and why it has historically resisted systemic treatment.

Experts Bridge Oncology and Neurology to Catch LEMS Earlier in SCLC: With Misty D. Shields, MD, PhD; Triparna Sen, MD, PhD, MS; and Ditte Primdahl, MD

ByMisty D. Shields, MD, PhD,Triparna Sen, PhD,Ditte Primdahl, MD

July 28th 2026

Lung cancer and neurology experts discuss the ties between cancer-associated LEMS and small cell lung cancer, diagnostic tips, and management strategies.

FDA Approval Insights: Orca-T Raises the Bar for Allogeneic Transplants in Hematologic Malignancies: With Everett Meyer, MD, PhD

ByEverett Meyer, MD, PhD

July 28th 2026

Everett Meyer, MD, PhD, discusses the significance of the FDA approval of Orca-T for patients with hematologic malignancies.

ASCO 2026 ADC Data Clarify Some Strategies and Raise Further Questions for Breast Cancer Care: With Paolo Tarantino, MD, PhD

ByPaolo Tarantino, MD

July 27th 2026

Dr Tarantino discusses practice-informing data regarding antibody-drug conjugates in breast cancer that were presented at the 2026 ASCO Annual Meeting.

FDA Approval Insights: First-Line Sacituzumab Govitecan Plus Pembrolizumab for PD-L1+ TNBC: With Sara M. Tolaney, MD, MPH

BySara M. Tolaney, MD, MPH

July 27th 2026

Dr Tolaney discusses the FDA approval of first-line sacituzumab govitecan plus pembrolizumab for locally advanced or metastatic PD-L1–positive TNBC.

FDA Approval Insights: Orally Disintegrating Nilotinib Tablets for CML: With Jorge E. Cortes, MD; and Elias Jabbour, MD

ByJorge Cortes, MD,Elias Jabbour, MD

July 27th 2026

Dr Cortes and Dr Jabbour discuss the orally disintegrating tablet formulation of nilotinib and its June 2026 FDA approval for patients with CML.

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

July 24th 2026

OncLive On Air® CE

Joshua K. Sabari, MD, assistant professor in the Department of Medicine at NYU Grossman School of Medicine, and director of High Reliability Organization Initiatives at NYU Langone Health’s Perlmutter Cancer Center

Treat Early and Aggressively: Optimizing Small Cell Lung Cancer Management Across the Community Setting: With Joshua K. Sabari, MD

ByJoshua K. Sabari, MD

July 24th 2026

Joshua K. Sabari, MD, discusses the complexities of managing SCLC across both academic and community settings.

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

July 23rd 2026

OncLive On Air® CE

Sara Nunnery, MD, MSCI, breast medical oncologist, director, Breast Cancer Research, Tennessee Oncology in Nashville; Maelee Yang, MD, plastic surgeon, The Surgical Clinic; Odette Abou Ghanem, MD, assistant professor, plastic and reconstructive surgery, plastic and reconstructive surgeon, Vanderbilt University Medical Center

Post-Breast Cancer Reconstruction Options Center Patient Preferences and Oncologic Expertise: With Sara Nunnery, MD, MSCI; Maelee Yang, MD; and Odette Abou Ghanem, MD

BySara Nunnery, MD, MSCI,Maelee Yang, MD ,Odette Abou Ghanem, MD

July 21st 2026

Drs Nunnery, Yang, and Abou Ghanem discuss available breast reconstruction options following breast cancer surgery.

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

July 21st 2026

OncLive On Air® CE

DLBCL 2026 UPDATE

BySamantha A. Armstrong, MD,Karine Tawagi, MD

July 20th 2026

Two Onc Docs delivers a comprehensive, board-focused review of DLBCL for 2026, updating their prior coverage to reflect several recent practice changes.

Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC

July 20th 2026

OncLive On Air® CE

Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis

July 17th 2026

OncLive On Air® CE

Neil D. Gross, MD, FACS, The University of Texas MD Anderson Cancer Center

Navigating Systemic Therapy Selection and Sequencing in Advanced CSCC: With Neil D. Gross, MD, FACS

ByNeil D. Gross, MD, FACS

July 17th 2026

Dr Gross discusses the key biological and clinical distinctions between cutaneous squamous cell carcinoma and basal cell carcinoma.

Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology

July 16th 2026

OncLive On Air® CE

Oncology Town Hall: Updates From Chicago: Oral SERDs in HR+/HER2– Metastatic Breast Cancer—What the Latest Data Really Tell Us

July 15th 2026

OncLive On Air® CE

Cases and Conversations™: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

July 14th 2026

OncLive On Air® CE

RECITE Findings Highlight the Potential of Romiplostim to Preserve Chemotherapy Delivery in GI Cancer: With Gerald Soff, MD

ByGerald Soff, MD

July 13th 2026

Gerald Soff, MD, discusses the phase 3 RECITE trial, which evaluated romiplostim for the treatment of persistent chemotherapy-induced thrombocytopenia in patients with GI cancer.

Medical Crossfire®: Closing Clinical Practice Gaps in Hepatobiliary Cancer With Emerging Immunotherapies and Delivery Innovations

July 13th 2026

OncLive On Air® CE

Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

July 10th 2026

OncLive On Air® CE

FDA Approval Insights: Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma: With Alex Herrera, MD

ByAlex Herrera, MD

July 9th 2026

Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for untreated classical Hodgkin lymphoma.

Podcasts

Recent Episodes

All series

Oncology Unplugged With Dr Chandler Park

Pediatrics

Breast Cancer Briefing

Marvels in Medicine

Talking Tumors

Biomarker Consortium

State of the Science Summits

From Discovery to Delivery: Charting Progress in Gynecologic Oncology

OncLive on Air Powered by PER

Roundtable Discussions

Fellowship

Disparities

Rare Cancers

Women In Oncology

Conference Perspectives

OncClub

Oncology Expert Insights

FDA Approval Insights

Blood Club

Two Onc Docs

Cancer, Character, and Calling

How This Is Building Me

All Podcasts

Greater Flexibility and Improved QOL Represent Key Potential Benefits With Liquid TKI Formulations: With Jonathan Trent, MD, PhD

An Ophthalmologist Guides Oncologists and Patients Through ADC-Related Eye Toxicities: With Sara Nunnery, MD, MSCI; and Sarah Sunshine, MD

From Trials to the Clinic: Incorporating New Advances in Metastatic TNBC

FDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS

Positioning PD-L1/VEGF Bispecifics in First-Line Non–Small Cell Lung Cancer: With Solange Peters, MD, PhD

Precision Oncology, Bispecific Antibodies, and Next-Generation Targeted Therapies Are Reshaping NSCLC Care: With Chandler Park, MD; Stephen V. Liu, MD

Biomarker-Driven Shifts Signal the Next Generation of mCRC Therapies: With Tanios S. Bekaii-Saab, MD

Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD

Sequencing Systemic and Liver-Directed Therapy in HLA-A*02:01–Negative Metastatic Uveal Melanoma: With Marlana M. Orloff, MD

Experts Bridge Oncology and Neurology to Catch LEMS Earlier in SCLC: With Misty D. Shields, MD, PhD; Triparna Sen, MD, PhD, MS; and Ditte Primdahl, MD

FDA Approval Insights: Orca-T Raises the Bar for Allogeneic Transplants in Hematologic Malignancies: With Everett Meyer, MD, PhD

ASCO 2026 ADC Data Clarify Some Strategies and Raise Further Questions for Breast Cancer Care: With Paolo Tarantino, MD, PhD

FDA Approval Insights: First-Line Sacituzumab Govitecan Plus Pembrolizumab for PD-L1+ TNBC: With Sara M. Tolaney, MD, MPH

FDA Approval Insights: Orally Disintegrating Nilotinib Tablets for CML: With Jorge E. Cortes, MD; and Elias Jabbour, MD

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

Treat Early and Aggressively: Optimizing Small Cell Lung Cancer Management Across the Community Setting: With Joshua K. Sabari, MD

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

Post-Breast Cancer Reconstruction Options Center Patient Preferences and Oncologic Expertise: With Sara Nunnery, MD, MSCI; Maelee Yang, MD; and Odette Abou Ghanem, MD

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

DLBCL 2026 UPDATE

Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC

Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis

Navigating Systemic Therapy Selection and Sequencing in Advanced CSCC: With Neil D. Gross, MD, FACS

Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology

Oncology Town Hall: Updates From Chicago: Oral SERDs in HR+/HER2– Metastatic Breast Cancer—What the Latest Data Really Tell Us

Cases and Conversations™: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

RECITE Findings Highlight the Potential of Romiplostim to Preserve Chemotherapy Delivery in GI Cancer: With Gerald Soff, MD

Medical Crossfire®: Closing Clinical Practice Gaps in Hepatobiliary Cancer With Emerging Immunotherapies and Delivery Innovations

Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

FDA Approval Insights: Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma: With Alex Herrera, MD

Trending on OncLive

Phase 3 VERSATILE-003 Trial of PDS0101 in HNSCC Is Discontinued

CD24 Expression Confers Resistance to Anti–PD-1 Therapy in NSCLC, RET-TKI Dose Reductions Do Not Compromise Outcomes in RET+ Disease

FDA Advisory Committee to Review Premarket Approval Application for Multi-Cancer Early Detection Test

Dr Silverstein on the Efficacy of Abemaciclib and Hormonal Therapy in Recurrent Ovarian and Endometrial Cancer

T-DXd Plus Pertuzumab Is Approved in China for First-Line HER2+ Metastatic Breast Cancer